IS2884B - Kínasólínafleiður - Google Patents

Kínasólínafleiður

Info

Publication number
IS2884B
IS2884B IS8714A IS8714A IS2884B IS 2884 B IS2884 B IS 2884B IS 8714 A IS8714 A IS 8714A IS 8714 A IS8714 A IS 8714A IS 2884 B IS2884 B IS 2884B
Authority
IS
Iceland
Prior art keywords
kínasólínafleiður
Prior art date
Application number
IS8714A
Other languages
English (en)
Other versions
IS8714A (is
Inventor
Nicola Murdoch Heron
Andrew Austen Mortlock
Frederic Henri Jung
Georges Rene Pasquet
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS8714A publication Critical patent/IS8714A/is
Publication of IS2884B publication Critical patent/IS2884B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS8714A 2002-12-24 2008-02-13 Kínasólínafleiður IS2884B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02293238 2002-12-24
EP03291315 2003-06-02

Publications (2)

Publication Number Publication Date
IS8714A IS8714A (is) 2008-02-13
IS2884B true IS2884B (is) 2014-06-15

Family

ID=32683824

Family Applications (2)

Application Number Title Priority Date Filing Date
IS7948A IS2504B (is) 2002-12-24 2005-07-20 Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra
IS8714A IS2884B (is) 2002-12-24 2008-02-13 Kínasólínafleiður

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IS7948A IS2504B (is) 2002-12-24 2005-07-20 Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra

Country Status (30)

Country Link
US (4) US7528121B2 (is)
EP (2) EP1847539B1 (is)
JP (3) JP4422102B2 (is)
KR (1) KR101010299B1 (is)
AR (2) AR042668A1 (is)
AT (2) ATE438644T1 (is)
AU (1) AU2003290313B2 (is)
BR (1) BRPI0317717B8 (is)
CA (1) CA2511613C (is)
CL (1) CL2003002731A1 (is)
CY (2) CY1107775T1 (is)
DE (2) DE60315892T2 (is)
DK (2) DK1847539T3 (is)
ES (2) ES2329623T3 (is)
HK (2) HK1080481A1 (is)
IL (2) IL169112A (is)
IS (2) IS2504B (is)
MX (1) MXPA05006918A (is)
MY (2) MY147761A (is)
NO (2) NO335193B1 (is)
NZ (1) NZ540698A (is)
PL (2) PL223998B1 (is)
PT (2) PT1578755E (is)
RU (3) RU2350611C1 (is)
SA (1) SA04240504B1 (is)
SI (2) SI1847539T1 (is)
TW (2) TWI336327B (is)
UA (1) UA83814C2 (is)
UY (1) UY28149A1 (is)
WO (1) WO2004058781A1 (is)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE446093T1 (de) * 2001-12-24 2009-11-15 Astrazeneca Ab Substituierte chinazolin-derivate als aurora- kinase inhibitoren
MXPA05006920A (es) * 2002-12-24 2006-02-10 Astrazeneca Ab Compuestos de quinazolina.
US7528121B2 (en) * 2002-12-24 2009-05-05 Astrazeneca Ab Phosphonooxy quinazoline derivatives and their pharmaceutical use
ATE390422T1 (de) * 2003-04-16 2008-04-15 Astrazeneca Ab Quinazolin-derivate für die behandling von krebs
JP4939220B2 (ja) * 2003-05-15 2012-05-23 アークル インコーポレイテッド ｐ３８の阻害物質としてのイミダゾチアゾール類およびイミダゾオキサゾール誘導体
WO2004105764A1 (en) * 2003-06-02 2004-12-09 Astrazeneca Ab (3- ((quinazolin-4-yl) amino )-1h-pyrazol-1-yl) acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
BRPI0516093A (pt) * 2004-10-12 2008-08-19 Astrazeneca Ab derivado de quinazolina, processo para a preparação do mesmo, composição farmacêutica, uso de um derivado de quinazolina, e, método para tratamento de distúrbios proliferativos celulares em um animal de sanque quente
EP1802608A1 (en) * 2004-10-12 2007-07-04 AstraZeneca AB Quinazoline derivatives for use against cancer
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
WO2006044869A1 (en) * 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
US7501430B2 (en) * 2006-04-17 2009-03-10 Arqule, Inc. RAF inhibitors and their uses
GB0609617D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination
EA200970361A1 (ru) 2006-10-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Ингибиторы киназы
US20110136766A1 (en) * 2008-03-04 2011-06-09 Vitae Pharmaceuticals, Inc. Aurora kinase inhibitors
US20110033461A1 (en) * 2008-03-12 2011-02-10 Vladimir Ratushny Combination Therapy for the Treatment of Cancer
US8138194B2 (en) 2008-04-30 2012-03-20 National Health Research Institutes Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
US20110269758A1 (en) * 2008-07-03 2011-11-03 Merck Patent Gmbh Naphthyridinones as protein kinase inhibitors
KR20110100241A (ko) * 2008-12-05 2011-09-09 아르퀼 인코포레이티드 Ｒａｆ 억제제 및 이들의 용도
US7863325B2 (en) 2008-12-11 2011-01-04 Axcentua Pharmaceuticals Ab Crystalline genistein sodium salt dihydrate
US9012495B2 (en) 2008-12-11 2015-04-21 Axcentua Pharmaceuticals Ab Crystalline forms of genistein
MX2011006725A (es) 2008-12-22 2011-09-15 Millennium Pharm Inc Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
US9604963B2 (en) 2011-03-04 2017-03-28 Glaxosmithkline Intellectual Property Development Limited Amino-quinolines as kinase inhibitors
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AU2014216178B2 (en) 2013-02-15 2018-06-28 KALA BIO, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
EP3763710A1 (en) 2013-02-20 2021-01-13 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
BR112015019624A2 (pt) 2013-02-21 2017-07-18 Glaxosmithkline Ip Dev Ltd quinazolinas como inibidores de quinase
RU2682332C2 (ru) 2013-09-16 2019-03-19 Астразенека Аб Терапевтические полимерные наночастицы и способы их получения и применения
NZ719185A (en) 2013-11-01 2017-11-24 Kala Pharmaceuticals Inc Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
JP6525474B2 (ja) 2013-12-06 2019-06-05 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
WO2017015316A1 (en) 2015-07-21 2017-01-26 Millennium Pharmaceuticals, Inc. Administration of aurora kinase inhibitor and chemotherapeutic agents
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509422A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
BR112020004559A2 (pt) 2017-09-08 2020-09-24 The Board Of Trustees Of The Leland Stanford Junior University inibidores de enpp1 e seus usos para o tratamento de câncer
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN112939948B (zh) * 2019-12-11 2022-05-17 苏州美诺医药科技有限公司 新型含喹唑啉类化合物及其中间体与应用
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
WO2022192139A1 (en) 2021-03-10 2022-09-15 Astrazeneca Ab Aurora kinase b inhibitors for use for treating cancer

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
DE69222637T2 (de) 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
WO1995033724A1 (en) 1994-06-09 1995-12-14 Glaxo Group Limited Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (is) 1994-11-12 1997-12-01 Zeneca Ltd
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PT868519E (pt) 1995-12-18 2006-05-31 Sugen Inc Diagnostico e tratamento de disturbios relacionados com aur-1 e/ou aur-2
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
ES2194181T3 (es) 1996-02-13 2003-11-16 Astrazeneca Ab Derivados de quinazolina como inhibidores de vegf.
DK0885198T3 (da) 1996-03-05 2002-03-25 Astrazeneca Ab 4-Anilinoquinazolinderivater
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ES2241324T3 (es) * 1998-10-08 2005-10-16 Astrazeneca Ab Derivados de quinazolina.
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
KR20020032612A (ko) 1999-09-21 2002-05-03 다비드 에 질레스 퀴나졸린 유도체 및 그의 의약으로서의 용도
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
US7030123B2 (en) 2000-05-31 2006-04-18 Astrazeneca Ab Indole derivatives with vascular damaging activity
MXPA02011974A (es) * 2000-06-28 2004-09-06 Astrazeneca Ab Derivados de quinazolina sustituidos y su uso como inhibidores.
AU6623201A (en) 2000-07-07 2002-02-05 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
JP2004502766A (ja) 2000-07-07 2004-01-29 アンギオジェン・ファーマシューティカルズ・リミテッド 血管損傷剤としてのコルヒノール誘導体
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2003000188A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
GB0124299D0 (en) * 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
ATE446093T1 (de) 2001-12-24 2009-11-15 Astrazeneca Ab Substituierte chinazolin-derivate als aurora- kinase inhibitoren
US7528121B2 (en) * 2002-12-24 2009-05-05 Astrazeneca Ab Phosphonooxy quinazoline derivatives and their pharmaceutical use
MXPA05006920A (es) * 2002-12-24 2006-02-10 Astrazeneca Ab Compuestos de quinazolina.
ATE390422T1 (de) * 2003-04-16 2008-04-15 Astrazeneca Ab Quinazolin-derivate für die behandling von krebs

Also Published As

Publication number Publication date
IS7948A (is) 2005-07-20
DE60315892D1 (de) 2007-10-04
BRPI0317717B1 (pt) 2017-12-19
TW201102369A (en) 2011-01-16
MY147761A (en) 2013-01-31
IL185176A0 (en) 2007-12-03
NO20052855D0 (no) 2005-06-13
MY136174A (en) 2008-08-29
RU2357971C2 (ru) 2009-06-10
JP2007326862A (ja) 2007-12-20
KR20050088333A (ko) 2005-09-05
TW200510342A (en) 2005-03-16
US8268841B2 (en) 2012-09-18
TWI393710B (zh) 2013-04-21
IS8714A (is) 2008-02-13
AU2003290313A1 (en) 2004-07-22
NO335446B1 (no) 2014-12-15
IL169112A (en) 2010-12-30
EP1578755A1 (en) 2005-09-28
PL377680A1 (pl) 2006-02-06
RU2005123485A (ru) 2006-03-10
ES2290529T3 (es) 2008-02-16
DE60315892T2 (de) 2008-08-14
CY1109479T1 (el) 2014-08-13
EP1847539A1 (en) 2007-10-24
HK1080481A1 (en) 2006-04-28
BR0317717A (pt) 2005-11-22
US9567358B2 (en) 2017-02-14
NO335193B1 (no) 2014-10-20
RU2350611C1 (ru) 2009-03-27
CA2511613C (en) 2012-10-02
JP4906608B2 (ja) 2012-03-28
SI1578755T1 (sl) 2007-12-31
ES2329623T3 (es) 2009-11-27
JP2009046514A (ja) 2009-03-05
BRPI0317717B8 (pt) 2021-05-25
UY28149A1 (es) 2004-07-30
ATE438644T1 (de) 2009-08-15
IL169112A0 (en) 2009-02-11
IL185176A (en) 2011-10-31
DK1578755T3 (da) 2007-11-12
PL412704A1 (pl) 2015-10-12
AR042668A1 (es) 2005-06-29
AR057753A2 (es) 2007-12-19
PT1578755E (pt) 2007-10-19
AU2003290313B2 (en) 2007-05-10
PL221490B1 (pl) 2016-04-29
JP2006512418A (ja) 2006-04-13
NO20052855L (no) 2005-08-03
RU2007121850A (ru) 2008-12-20
CA2511613A1 (en) 2004-07-15
US20140162984A1 (en) 2014-06-12
MXPA05006918A (es) 2005-08-18
KR101010299B1 (ko) 2011-01-25
JP4422102B2 (ja) 2010-02-24
US20150307534A1 (en) 2015-10-29
ATE370958T1 (de) 2007-09-15
SA04240504A (ar) 2005-12-03
NZ540698A (en) 2008-05-30
NO20131444L (no) 2005-08-03
CY1107775T1 (el) 2013-06-19
DK1847539T3 (da) 2009-11-09
PT1847539E (pt) 2009-10-06
EP1847539B1 (en) 2009-08-05
SA04240504B1 (ar) 2008-04-01
CL2003002731A1 (es) 2005-01-07
WO2004058781A1 (en) 2004-07-15
DE60328735D1 (de) 2009-09-17
TWI336327B (en) 2011-01-21
UA83814C2 (ru) 2008-08-26
SI1847539T1 (sl) 2010-01-29
EP1578755B1 (en) 2007-08-22
IS2504B (is) 2009-04-15
US9018191B2 (en) 2015-04-28
US20060116357A1 (en) 2006-06-01
JP4503090B2 (ja) 2010-07-14
US20100069412A1 (en) 2010-03-18
PL223998B1 (pl) 2016-11-30
US7528121B2 (en) 2009-05-05
HK1111417A1 (en) 2008-08-08

Similar Documents

Publication Publication Date Title
ATE457980T1 (de) Aryloxime
ATE534648T1 (de) C-6-modifizierte indazolylpyrrolotriazine
IS2884B (is) Kínasólínafleiður
DE50305852D1 (de) Einspritzventil
DE50310083D1 (de) Phthalocyaninpigmentzubereitungen
ATE318817T1 (de) Aza-arylpiperazine
ATE427876T1 (de) Luftkissenboot
DE50212360D1 (de) Anfahrhilfesteuerungsvorrichtung
DE50212349D1 (de) Hirurgie
DE50301200D1 (de) Wischblatt
ATE349458T1 (de) Etonogestrelester
DE50305301D1 (de) Einspritzventil
DE50309536D1 (de) Fadenabsaugvorrichtung
ATA1572002A (de) Managementspleisskassette
NO20052813D0 (no) Celecoxib-promedikament
DE50309499D1 (de) Librierwerkzeugen
DE50302660D1 (de) Stopfmachine
ATE469773T1 (de) Zugöse
ATA4142004A (de) Trägerverbau
DE50303317D1 (de) Einschub-leistungsschalter
ATA19152002A (de) Hubkupplung
DE50310701D1 (de) Magnetfuehrungseinrichtung
DE50308979D1 (de) Einspritzventil
DE10244834B8 (de) Suszeptometer
DE50300322D1 (de) Zylinderkopfdichtung